M. Crispin

Impact of Glycan Depletion, Glycan Debranching and Increased Glycan Charge on HIV-1 Neutralization Sensitivity and Immunogenicity

This study evaluates glycoengineered HIV-1 trimers to enhance bNAb recognition, finding that B4GalT1+ST6GalT1 modifications increase antibody titers in infected donors but reduce vaccine-induced neutralizing antibodies.

Different vaccine platforms result in distinct antibody responses to the same antigen in haemodialysis patients

This study compares antibody responses in haemodialysis patients after vaccination with different platforms, finding mRNA vaccines induce better functional responses than viral vectors.

Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines

The paper introduces a triple tandem trimer (TTT) design for HIV-1 Env and influenza HA immunogens, showing improved trimer-specific immune responses in viral vectored vaccines.

Bespoke conformation and antibody recognition distinguishes the streptococcal immune evasion factors EndoS and EndoS2

This study compares the structural differences between EndoS and EndoS2 to explain their distinct IgG recognition and immune evasion mechanisms.

Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization

This study investigates how glycan heterogeneity on HIV-1 Env contributes to persistent infectivity despite neutralizing antibody (NAb) treatment, showing that glycan variants affect antibody binding and neutralization efficacy.

Focusing antibody responses to the fusion peptide in rhesusmacaques

This study uses continuous immunogen delivery in rhesus macaques to focus antibody responses on the HIV fusion peptide, identifying key residues for vaccine design.

Impact of Common Modifications on the Antigenic Profile and Glycosylation of Membrane-Expressed HIV-1 Envelope Glycoprotein.

This study evaluates how stabilizing mutations in HIV-1 Env affect trimer stability, antigenicity, and glycosylation when expressed on membrane-expressed VLPs, finding some mutations reduce neutralizing antibody binding and alter glycan processing.

Mechanisms of SARS-CoV-2 Inactivation using UVC Laser Radiation

This study investigates the inactivation of SARS-CoV-2 using UVC laser radiation and identifies mechanisms involving RNA damage and disruption of spike protein function.

Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies

The paper structures and characterizes Lassa virus glycoproteins from multiple lineages and identifies neutralizing antibodies that target conserved epitopes.

The diversity of the glycan shield of sarbecoviruses closely related to SARS-CoV-2

This study compares the glycan shields of sarbecoviruses to understand how sequence variations affect their structure and potential for antibody neutralization.

Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimers as HIV-1 vaccine candidates

Glycan trimming of HIV-1 Env immunogens improves vaccine-induced neutralizing antibody responses in small animals and primates.

Extensive substrate recognition by the streptococcal antibody-degrading enzymes IdeS and EndoS

This study presents crystal structures of IdeS and EndoS in complex with IgG1 Fc, revealing their distinct mechanisms of antibody recognition and cleavage.

Lassa virus glycoprotein nanoparticles elicit a neutralizing antibody that defines a new site of vulnerability

This study develops Lassa virus glycoprotein nanoparticles that stabilize GPC trimers and elicit neutralizing antibodies targeting a new vulnerability site.

Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus

This study identifies nAbs against SIVmac239, reveals structural features of its Env trimer, and shows passive transfer of nAbs protects macaques from infection.

Structure of the hepatitis C virus E1E2 glycoprotein complex

The paper presents the cryo-EM structure of the HCV E1E2 glycoprotein complex with antibodies, revealing the E1-E2 interface and its stabilization mechanisms.

Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens

This paper engineers HIV-1 envelope trimers with enhanced V2 and fusion peptide neutralization sensitivity for vaccine development.

Uncovering cryptic pockets in the SARS-CoV-2 spike glycoprotein

This study identifies a novel cryptic pocket on the SARS-CoV-2 spike protein using molecular dynamics simulations and validates its druggable potential through experimental methods.

Site-specific steric control of SARS-CoV-2 spike glycosylation

The paper compares glycosylation patterns of recombinant SARS-CoV-2 spike proteins across labs with infectious virus S protein, finding conserved site-specific glycan maturation stalling linked to protein structure.

Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM

The paper uses cryoEM to analyze polyclonal antibody responses to HIV Env immunogens in rhesus macaques, revealing structural differences in antibody binding and immunogenicity of engineered mutations and glycan sites.

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine

This study characterizes the structure, conformation, and glycosylation of the SARS-CoV-2 spike protein expressed by the ChAdOx1 nCoV-19/AZD1222 vaccine, confirming its native-like properties.

Neutralizing antibodies induced by first-generation gp41-stabilized HIV-1 envelope trimers and nanoparticles

This study isolates HIV-1 neutralizing antibodies from mice and rabbits immunized with gp41-stabilized trimers and nanoparticles, showing they target different epitopes and elicit Env-dependent breadth.

Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles

This study shows that displaying HIV-1 Env trimers on two-component protein nanoparticles enhances autologous Tier-2 neutralizing antibody titers in rabbits.

Molecular architecture of the SARS-CoV-2 virus

This study reveals the molecular architecture of the SARS-CoV-2 virus using cryo-ET and STA, showing the structure of S proteins, N-linked glycans, and RNPs.

Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike

The paper modifies HIV-1 Env trimers to increase glycan occupancy and reduce artificial glycan holes, improving vaccine antigen design.

Site-specific analysis of the SARS-CoV-2 glycan shield

The paper uses mass spectrometry to analyze glycan structures on the SARS-CoV-2 spike protein, revealing differences from host glycan processing and implications for vaccine design.

Networks of HIV-1 envelope glycans maintain antibody epitopes in the face of glycan additions and deletions

The paper investigates how HIV-1 envelope glycan networks affect the formation and stability of broadly neutralizing antibody epitopes, showing their importance in immunogen design.

Vulnerabilities in coronavirus glycan shields despite extensive glycosylation

This study identifies vulnerabilities in coronavirus glycan shields by showing that MERS S protein has under-processed oligomannose-type glycan clusters, unlike SARS and HKU1 CoVs, and that these glycans do not form an effective shield against antibodies.

Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens

The paper evaluates de novo-designed two-component nanoparticles for presenting HIV Env trimers, showing improved antibody responses through multivalent display.

Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics

This study compares native HIV-1 Env trimers with soluble SOSIP trimers, finding structural and antigenic similarities but differences in antibody binding and glycan composition.

Chimpanzee SIV Envelope trimer: structure and deployment as an HIV vaccine template

The paper describes the structure of a chimpanzee SIV Env trimer and shows it induces HIV V2-specific neutralizing antibodies in mice.